1. Home
  2. MGX vs RCT Comparison

MGX vs RCT Comparison

Compare MGX & RCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MGX
  • RCT
  • Stock Information
  • Founded
  • MGX 2018
  • RCT 2014
  • Country
  • MGX United States
  • RCT United Kingdom
  • Employees
  • MGX N/A
  • RCT N/A
  • Industry
  • MGX
  • RCT
  • Sector
  • MGX
  • RCT
  • Exchange
  • MGX NYSE
  • RCT NYSE
  • Market Cap
  • MGX 62.1M
  • RCT 68.1M
  • IPO Year
  • MGX 2024
  • RCT 2025
  • Fundamental
  • Price
  • MGX $2.08
  • RCT $2.03
  • Analyst Decision
  • MGX Strong Buy
  • RCT Strong Buy
  • Analyst Count
  • MGX 4
  • RCT 2
  • Target Price
  • MGX $13.00
  • RCT $5.00
  • AVG Volume (30 Days)
  • MGX 916.2K
  • RCT 5.0M
  • Earning Date
  • MGX 08-13-2025
  • RCT 05-17-2025
  • Dividend Yield
  • MGX N/A
  • RCT N/A
  • EPS Growth
  • MGX N/A
  • RCT N/A
  • EPS
  • MGX N/A
  • RCT N/A
  • Revenue
  • MGX $45,263,000.00
  • RCT $46,499,285.00
  • Revenue This Year
  • MGX N/A
  • RCT N/A
  • Revenue Next Year
  • MGX $11.75
  • RCT N/A
  • P/E Ratio
  • MGX N/A
  • RCT N/A
  • Revenue Growth
  • MGX N/A
  • RCT 134.76
  • 52 Week Low
  • MGX $1.23
  • RCT $1.17
  • 52 Week High
  • MGX $5.49
  • RCT $5.36
  • Technical
  • Relative Strength Index (RSI)
  • MGX 62.36
  • RCT N/A
  • Support Level
  • MGX $2.04
  • RCT N/A
  • Resistance Level
  • MGX $2.47
  • RCT N/A
  • Average True Range (ATR)
  • MGX 0.18
  • RCT 0.00
  • MACD
  • MGX 0.07
  • RCT 0.00
  • Stochastic Oscillator
  • MGX 61.76
  • RCT 0.00

About MGX METAGENOMI INC

Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. The genome editing toolbox includes systems for making small edits such as programmable nucleases, base editors, small RNA-mediated integration systems (RIGS), as well as large gene integration systems including large template RIGS and CRISPR-associated transposases (CASTs). The company is focused on its vivo gene editing for its wholly-owned pipeline while pursuing technology out licensing for ex vivo cell therapy. Its pipeline includes product candidates aimed at addressing disorders like Hemophilia A (through MGX-001), Refractory Hypertension, Cardiovascular diseases, and Wilson's disease, among others.

About RCT REDCLOUD HOLDINGS PLC

RedCloud Holdings PLC developed and operates the RedCloud Platform, which facilitates the trading of everyday consumer supplies of fast-moving consumer goods (FMCG) products across business supply chains. The Platform solves old problem of how to unlock and enable access of key purchase and sales data between brands, distributors and retailers in growth consumer markets. Its Platform has AI and machine learning capabilities that provide brands, distributors and retailers with trading and product insights and data to help make commercial decisions regarding their business operations. Geographically, Key revenue is generated from Nigeria.

Share on Social Networks: